Madrigal Pharmaceuticals

MDGL

Market cap $9.81B

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M.

MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript

Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago.

Fourth -quarter and full-year 2025 Rezdiffra ® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025 , more than 36,250 patients on Rezdiffra Built industry-leading MASH pipeline with more than 10 programs at multiple stages of development Reports cash, cash equivalents, restricted cash and marketable securities of $988.6 million as of Dec. 31, 2025 Company to host conference call today, Feb. 19, 2026, at 8 a.m. EST CONSHOHOCKEN, Pa.

CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on February 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Madrigal Pharmaceuticals is reiterated as a Strong Buy ahead of Q4 earnings, with a 12-month price target of $665, implying 43% upside. Rezdiffra's rapid commercialization and first-mover advantage in the MASH market underpin robust sales growth, with Q3 net sales at $287.3M and >29,500 active patients. Geographic expansion in Europe, pipeline catalysts (F4 trial), and under-diagnosis of MASH provide a long growth runway and potential for upside surprises.

Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.

Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.

Madrigal (MDGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.